Overview of Ciprofibrato PL

Property	Description
Active ingredient	Ciprofibrate
Form	Oral tablets or capsules
Pharmacological class	Fibrate (Fibric Acid Derivative)
General purpose	Correcting blood fat imbalances (Dyslipidemia)
Origin	Synthetic compound
Route of administration	Oral (by mouth)

What Type of Medicine is Ciprofibrate?

Ciprofibrato PL is a specific trade name for a prescription-only medication containing the single active ingredient, Ciprofibrate. Ciprofibrate is pharmacologically classified as a fibrate, placing it within the larger group of lipid-lowering agents used for regulating fat levels in the blood. The efficacy of Ciprofibrate in this role is clinically recognized and supported by established pharmacological studies. This medicine, recognized by its International Nonproprietary Name (INN) Ciprofibrate, is a synthetic compound, chemically identified as a fibric acid derivative. Its distinct mechanism allows it to offer a targeted approach for managing complex lipid profile abnormalities.

Ciprofibrato PL: Composition and Physical Form

This medication is administered via the oral route in solid oral dosage forms, commonly available as tablets or capsules. Ciprofibrato PL is characterized as a single-ingredient product, consisting only of the active substance, Ciprofibrate, combined with standard, non-active solid pharmaceutical excipients. This composition facilitates a standardized, measured dose for systemic absorption. The medicine's official classification places it under the ATC code C10AB08, confirming its defined purpose as a primary agent for cholesterol and triglyceride reduction.

What is the General Purpose of Ciprofibrate?

The general therapeutic purpose of Ciprofibrate is to exert a potent hypolipidemic action, assisting in the correction of a persistent imbalance of fats in the blood, commonly referred to as dyslipidemia. This medicine is effective at regulating fat metabolism, particularly by driving a significant reduction in elevated triglycerides and contributing to a favorable increase in protective High-Density Lipoprotein (HDL) cholesterol levels. Ciprofibrate is intended to be used as a vital component supporting and enhancing the effects of non-pharmacological measures, such as diet and exercise, in the management of a patient's fat profile.

Regulatory References

What side effects are possible with Ciprofibrato PL?

Possible side effects and safety information

The officially documented safety profile for Ciprofibrate is structured by frequency and the body system affected, based on regulatory standards like those established by the European Medicines Agency (EMA) and similar national authorities. This framework defines the risks associated with the medicine, focusing particularly on effects related to the musculoskeletal and hepatobiliary systems.

Frequency-Classified Adverse Reactions

Frequency Class	Associated Adverse Reactions (Examples from Regulatory Labels)
Common	Gastrointestinal disturbances (nausea, dyspepsia, diarrhea, vomiting), Headache, Dizziness, Myalgia (muscle pain).
Uncommon	Rhabdomyolysis, Alopecia, Hypersensitivity reactions (rash, pruritus, urticaria).
Rare	Cholelithiasis (gallstones), Pulmonary fibrosis, Pneumonitis.
Very Rare	Severe hepatic dysfunction.

Serious Adverse Reactions and Safety Constraints

The label documents serious adverse reactions, notably Rhabdomyolysis (severe muscle breakdown) and Severe Hepatic Dysfunction. Safety regulations mandate restrictions for use, and Ciprofibrate is contraindicated in patients with severe hepatic impairment, severe renal impairment, and pre-existing gallbladder disease.

Time-related patterns noted in regulatory texts include the possible observation of increased hepatic transaminases at the start of treatment. Furthermore, official safety requirements necessitate periodic monitoring of hepatic transaminases and Creatine Kinase (CK) levels throughout the treatment course, particularly when risk factors for muscle toxicity are present.

Overdose and Emergency Response

Overdose and when to seek help

If Ciprofibrato PL is taken in excess of the prescribed amount, official regulatory guidance mandates immediate medical attention. Users are instructed to talk to a doctor or go to a hospital straight away and to take the medicine pack when seeking urgent care.

Documented Manifestations and Severe Outcomes

The regulatory records indicate that there are no adverse events that are specific to overdosage for Ciprofibrate. However, in documented cases of significant high-dose exposure (e.g., 2800 mg), a severe muscular complication known as rhabdomyolysis has been reported. This outcome, which involves the muscular and renal systems, underscores the potential for severe consequences following high-level exposure.

Management and Monitoring

Clinical management must proceed without a specific counteracting agent, as the official prescribing information explicitly states that no specific antidotes to Ciprofibrate are known. Treatment is consequently symptomatic and supportive. Officially described procedures include implementing measures to prevent the further absorption of the drug from the gastro-intestinal tract, and gastric lavage may be instituted if considered necessary. Furthermore, regulatory documents note that Ciprofibrate is non-dialysable.

Therapeutic Uses of Ciprofibrato PL

What Ciprofibrato PL Treats: Main Uses and Benefits

Ciprofibrate is a lipid-regulating medicine applied in situations involving a systemic imbalance of blood fats, known as dyslipidemia. The medication is commonly used as a necessary adjunct to diet and lifestyle measures for correcting specific fat profiles.

This therapeutic domain addresses conditions such as Primary Hypertriglyceridaemia, Mixed Hyperlipidaemia, and situations involving abnormally low levels of protective HDL cholesterol. In clinical settings, the medication is often used to address markedly elevated triglyceride levels, and the primary benefit is the reduction of these fat particles, which may assist with managing the risk associated with acute conditions like pancreatitis.

The drug is relevant for individuals presenting with an unfavorable fat profile that is refractory to non-drug measures alone, often in patient groups such as adults with Type 2 Diabetes Mellitus. It provides supportive pharmacological assistance that contributes to functional stability in overall cardiovascular risk management.

“The therapy is relevant for supporting the long-term stabilization of the metabolic system.”

Quick Fact: Support for Atherogenic Risk Management

Ciprofibrate is commonly used to help manage the fat imbalances that create noticeable physiological strain on the vascular system, supporting patients with chronic systemic imbalance by easing the overall burden associated with the abnormal lipid profile.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Ciprofibrato PL

Ciprofibrato PL (Ciprofibrate) is approved for use in adults to manage specific types of hyperlipidaemia, typically as an adjunct to diet. However, official regulatory labeling outlines strict population exclusions and restrictions.

Contraindications (Absolute Non-Eligibility):

Severe Hepatic Impairment or Severe Renal Impairment (creatinine clearance <30 ml/min/1.73m^2)
Pregnancy and Lactation (including suspected pregnancy)
Hypersensitivity to Ciprofibrate or other fibrates, or history of fibrate-induced phototoxicity
Concurrent Use with another fibrate

Restricted or Conditional Use:

Moderate Renal Impairment: Requires a dosage reduction (e.g., to one tablet every other day) and careful monitoring.
Older Adults (Geriatric): Use requires caution, and dosage selection must be guided by assessed renal function.
Pediatric Population: Use is not recommended as safety and efficacy in children and adolescents have not been established.

The regulatory profile ensures that the medicine is reserved for the approved adult population free of severe organ impairment or specific metabolic risk factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ciprofibrate's interaction profile is based on restrictions and mandates documented in official regulatory sources, primarily concerning combined use with other lipid-modifying agents and highly protein-bound medications.

Formal Interaction Restrictions

Interaction Entity	Interaction Type	Regulatory Constraint
Other Fibrates (e.g., Gemfibrozil)	Pharmacodynamic (Additive risk)	Contraindicated (Prohibited co-administration due to severe muscle toxicity risk)
Oral Anticoagulants (e.g., Warfarin)	Pharmacokinetic (Protein binding displacement)	Requires frequent monitoring and dose adjustment (e.g., International Normalized Ratio - INR)
HMG-CoA Reductase Inhibitors (Statins)	Pharmacodynamic (Additive risk)	Use is generally not recommended or requires extreme caution due to elevated myopathy risk
Bile Acid Sequestrants (e.g., Cholestyramine)	Absorption Interference	Requires timing separation of at least two hours between administrations

Mechanism of Action

Ciprofibrate's action is defined by its highly specific manipulation of lipid metabolism at the genetic level, which results in the modulation of the production and catabolism of circulating fats. The mechanism is strictly non-indicational and involves targeted adjustment of regulatory pathways.

Activating the PPAR-alpha Control Switch

Ciprofibrate acts as an agonist that binds to and activates the Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha), a specialized nuclear transcription factor. This engagement directly influences the genetic machinery of liver cells, initiating a specific cascade that increases the expression of enzymes crucial for fat processing and concurrently suppresses the factors that inhibit fat clearance.

Accelerating Fat Breakdown and Clearance

By upregulating Lipoprotein Lipase (LPL) and suppressing its natural inhibitor, Apolipoprotein C-III (ApoC-III), Ciprofibrate accelerates the breakdown of triglyceride-rich lipoprotein particles (VLDL). This catabolic mechanism is the biological driver underlying the resulting major physiological change: a marked decrease in plasma triglyceride levels.

Modulating Cholesterol Components

The drug's activation of PPAR-alpha also stimulates the production of Apolipoprotein A-I (ApoA-I), the core protein of High-Density Lipoprotein (HDL). This mechanistic alteration facilitates the process of reverse cholesterol transport, which is the biological system responsible for moving excess cholesterol out of peripheral cells. This action leads to a resulting increase in HDL cholesterol concentrations.

Dosage and Administration Information

How to Use Ciprofibrato PL

Ciprofibrato PL is a medication used in a standardized manner, with strict dosing and administration rules established for this medication. Its application is always as an adjunct to a continuous, standard cholesterol-lowering diet, forming part of a long-term treatment plan for chronic lipid imbalances.

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral (by mouth)
Standard Dosing Schedule	The standard adult dose is one 100 mg tablet daily. This is the maximum recommended dose and must not be exceeded.
Timing in Relation to Meals	The tablet may be taken with or without food.
Tablet Integrity	The break line is solely to facilitate swallowing and is not intended to divide the tablet for administering smaller doses.
Frequency Pattern	Once daily

Population-Specific Use Rules

The dosage schedule requires specific adjustments based on kidney function. While dosing for older adults is generally the same as for other adults, the following procedural conditions apply:

Moderate Renal Impairment: For patients with moderate kidney function impairment (creatinine clearance 30-80 mL/min/1.73 m^2), the dosage must be reduced to one 100 mg tablet every other day.
Severe Renal Impairment: The medicine is restricted and should not be used in cases of severe kidney impairment.
Children: Use is not recommended as safety and efficacy data have not been established in this group.

If a dose is missed, the guidance is to skip the missed dose entirely and take the next dose at the regular scheduled time; double dosing to compensate is not allowed.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ciprofibrato PL

Evidence for Use in Primary Hypertriglyceridaemia

Ciprofibrato was studied for its application in conditions characterized by highly elevated blood triglyceride levels, known as primary hypertriglyceridaemia. The research mainly relies on Randomized Controlled Trials (RCTs) conducted over short-term to intermediate periods. Studies focused on how research monitored a patient's plasma triglyceride levels and other related fat particles. Studies described patterns related to measured changes in triglyceride levels in treated patient groups compared to controls. Direct evidence for Ciprofibrato regarding major long-term events, like heart attacks or strokes, is limited.

Research exploring clinical outcomes related to the heart and blood vessels over multiple years was evaluated in broad meta-analyses that combined data from the entire fibrate drug class. These pooled findings were observed in some studies to show mixed patterns when assessing these major clinical events. The extent of the long-term clinical outcome for Ciprofibrato specifically is not fully characterized.

Evidence for Use in Mixed Hyperlipidaemia

Research explored the use of Ciprofibrato in patients who presented with mixed hyperlipidaemia. This type of research included RCTs where the medicine was studied alone or alongside other therapies, particularly in adults with underlying conditions like Type 2 Diabetes Mellitus. Studies monitored changes in three primary lipid axes: triglycerides, HDL cholesterol, and non-HDL cholesterol.

Findings report how symptoms evolved in the observed populations, showing that studies described patterns related to simultaneous reductions in triglycerides and increases in HDL cholesterol over the study periods. The follow-up periods in these studies often focus on the intermediate-term, typically covering intervals up to six months. Evidence related to long-term patient outcomes over extended periods remains insufficient in the form of dedicated primary outcome trials.

What is Still Uncertain about Ciprofibrato PL

Evidence highlights what is known—and what is still uncertain—about the research base for Ciprofibrato. A primary limitation is the lack of dedicated, large-scale RCTs designed to measure the medicine's impact on major clinical outcomes over five years or more. Findings related to these long-term clinical outcomes are often inferred from broader fibrate class data, where the results were mixed and showed heterogeneity. Additionally, comparative evidence is lacking in some areas against newer lipid-regulating therapies, meaning its place relative to emerging treatments may still be evolving in the scientific literature.

Key Studies & References

US National Library of Medicine/MedlinePlus: Ciprofibrate (Oral Route)

Frequently Asked Questions (FAQ)

Common questions about Ciprofibrato PL (FAQ)

Q: Does Ciprofibrato PL interact with common pain relievers like Tylenol or Advil?

A: Official regulatory documents indicate that an interaction with certain non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen (a component of Advil) has been considered clinically important. However, there is no specific official warning regarding an interaction with acetaminophen (Tylenol) in the product information. Patients are generally advised to discuss all co-administered medications with a healthcare provider.

Q: How does Ciprofibrato PL specifically target VLDL cholesterol?

A: Official product information describes Ciprofibrato as a lipid-regulating medicine that works by influencing how the body processes fats. It is reported to reduce levels of both LDL (low-density lipoprotein) and VLDL (Very Low-Density Lipoprotein) cholesterol. Consequently, this action may lead to lower overall levels of triglycerides and cholesterol associated with those specific fat particles in the blood.

Q: Is there a generic version of Ciprofibrato PL available?

A: Yes, Ciprofibrato PL is a specific trade name for the active ingredient Ciprofibrate. Globally, Ciprofibrate is available under numerous other generic and brand names, depending on the country. The availability of generic versions is determined by local regulatory approvals and pharmacy supply.

Q: Does Ciprofibrato PL have any known food interactions?

A: Regulatory information states that Ciprofibrato PL tablets may be taken with or without food, meaning its absorption is not dependent on meals. Unlike some other lipid-regulating drugs, there is no specific warning in the official product information about interactions with common foods like grapefruit or grapefruit juice.

Q: Can Ciprofibrato PL affect how other medications are absorbed?

A: Yes, regulatory documents indicate that Ciprofibrato is highly protein bound in the bloodstream. This means it has the potential to displace other drugs from plasma protein binding sites, which may change how those other medications work. The concurrent use of Ciprofibrato with certain drugs, such as oral anticoagulants, typically necessitates careful medical monitoring.

Q: Is Ciprofibrato PL safe for people who have a history of gallstones?

A: Official labeling states the medicine is contraindicated (prohibited) in patients with pre-existing gallbladder disease. Additionally, cases of cholelithiasis (gallstones) have been reported as a rare side effect. This restriction is based on the potential risks linked to the drug's known effects on bile.

Q: What is the duration of action for Ciprofibrato PL in the body?

A: Pharmacokinetic data from regulatory documents show that the medicine has a relatively long elimination half-life, which is the time it takes for half of the drug to be cleared from the system. This long duration of action supports its prescribed once-daily dosing schedule.

Q: Can Ciprofibrato PL be crushed or split if it's hard to swallow?

A: The official patient information states that the tablet's scoring line is designed only to help make swallowing easier. The official documentation clarifies that the tablets are not intended to be divided. Regulatory guidance generally advises against altering solid dosage forms unless a healthcare provider approves.

Q: Are there any long-term effects of taking Ciprofibrato PL for many years?

A: Treatment with Ciprofibrato PL is often long-term, intended to manage chronic fat imbalances. While the drug's general safety profile is known, regulatory documents note that dedicated long-term clinical outcome data (such as its effect on major events over five years or more) are limited and often inferred from the broader fibrate drug class.

Q: Does Ciprofibrato PL require a specific time of day for best results?

A: The regulatory guidelines for Ciprofibrato PL prescribe a simple once-daily dose. Official administration guidelines do not mandate a specific time of day (morning or evening) for the medicine to be taken for optimal effectiveness.

Q: Is Ciprofibrato PL considered a first-line treatment for high lipids?

A: Official indications show that Ciprofibrato is intended for use as an adjunct to diet and other non-pharmacological treatments. It is typically prescribed for mixed hyperlipidaemia in situations where another common class of drug, like a statin, is either contraindicated or not tolerated by the patient.

Q: Can Ciprofibrato PL interact with grapefruit or grapefruit juice?

A: Based on the official product information, there is no specific warning listed regarding an interaction between Ciprofibrato PL and consuming grapefruit or grapefruit juice.

Q: Can Ciprofibrato PL cause skin sensitivity or rashes?

A: Yes, regulatory documents list hypersensitivity reactions such as rash and urticaria (hives) as uncommon side effects. Additionally, a history of fibrate-induced phototoxicity (an adverse skin reaction to sunlight) is listed as a contraindication, meaning the drug should not be used in such cases.

Q: Are there any known interactions between Ciprofibrato PL and alcohol?

A: Yes, official warnings note that chronic, excessive alcohol consumption is a risk factor that can increase the chance of muscle toxicity while taking this medicine. The patient leaflet highlights that consumption should be limited, as excessive alcohol use is noted as a factor that may increase the risk of muscle toxicity.

Q: How does Ciprofibrato PL contribute to regulating fats in the blood?

A: Ciprofibrato is considered a potent medicine for correcting fat imbalances, known as a hypolipidemic agent. According to official documents, its purpose is to cause a significant reduction in elevated triglycerides and contribute to a favorable increase in protective HDL (High-Density Lipoprotein) cholesterol levels.

How should Ciprofibrato PL be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Ciprofibrato PL are strictly defined by regulatory labeling to maintain quality and ensure safety.

Storage Scope	Requirement
Temperature Limit	Do not store above 25°C (Controlled Room Temperature).
Protection	Store in the original package to protect the tablets from moisture.
Safety	Keep the medicine out of the sight and reach of children.

To discard expired or unused Ciprofibrato PL, follow the official disposal instructions. The medicine should be disposed of via a governmental drug take-back program. If a program is unavailable, mix the tablets with an undesirable substance (like coffee grounds), seal the mixture, and place it in household trash. Do not flush this medicine down the toilet or pour it down a drain.

Ciprofibrato PL